Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice.
about
Regulation of atherogenesis by chemokines and chemokine receptorsSrc-dependent STAT-3-mediated expression of monocyte chemoattractant protein-1 is required for 15(S)-hydroxyeicosatetraenoic acid-induced vascular smooth muscle cell migrationEstrogen modulates TNF-alpha-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-beta activationProtective effects of tanshinone ⅡA on endothelial progenitor cells injured by tumor necrosis factor-α.Dominant-negative mutation of monocyte chemoattractant protein-1 prevents vulnerable plaques from rupture in rabbits independent of serum lipid levelsGenetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in miceRole of smooth muscle cells in the initiation and early progression of atherosclerosis.The attenuation of platelet and monocyte activation in a rabbit model of extracorporeal circulation by a nitric oxide releasing polymer.Role of NADPH oxidase in interleukin-4-induced monocyte chemoattractant protein-1 expression in vascular endothelium.Local gene silencing of monocyte chemoattractant protein-1 prevents vulnerable plaque disruption in apolipoprotein E-knockout miceInterleukin-4, Oxidative Stress, Vascular Inflammation and Atherosclerosis.Increased C-C chemokine receptor 2 gene expression in monocytes of severe obstructive sleep apnea patients and under intermittent hypoxiaPlasma NOV/CCN3 levels are closely associated with obesity in patients with metabolic disorders.Dihydrocapsaicin Attenuates Plaque Formation through a PPARγ/LXRα Pathway in apoE(-/-) Mice Fed a High-Fat/High-Cholesterol DietBlockade of CCR2 ameliorates progressive fibrosis in kidney.An agomir of miR-144-3p accelerates plaque formation through impairing reverse cholesterol transport and promoting pro-inflammatory cytokine production.Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets.L-cystathionine inhibits oxidized low density lipoprotein-induced THP-1-derived macrophage inflammatory cytokine monocyte chemoattractant protein-1 generation via the NF-κB pathwayAnti-monocyte chemoattractant protein-1 gene therapy for cardiovascular diseases.Thematic review series: The immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease.Decrease in circulating myeloid dendritic cell precursors in patients with intracranial large artery atherosclerosis.Mucosal Administration of Collagen V Ameliorates the Atherosclerotic Plaque Burden by Inducing Interleukin 35-dependent Tolerance.Chlorella 11-peptide inhibits the production of macrophage-induced adhesion molecules and reduces endothelin-1 expression and endothelial permeability.Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes.Chemokines as therapeutic targets for atherosclerotic plaque destabilization and rupture.The role of chemokines in recruitment of immune cells to the artery wall and adipose tissueXanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice.Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases.Therapeutic implications of chemokine-mediated pathways in atherosclerosis: realistic perspectives and utopias.Therapeutic strategies to deplete macrophages in atherosclerotic plaques.Biomarkers of plaque instability.Potential contributions of intimal and plaque hypoxia to atherosclerosis.Prospect and progress of gene therapy in treating atherosclerosis.Formyl Peptide Receptors in Cellular Differentiation and Inflammatory Diseases.Short-term changes in arterial inflammation predict long-term changes in atherosclerosis progression.Construction of biological networks from unstructured information based on a semi-automated curation workflow.Protease-Activated Receptor-2 Deficiency Attenuates Atherosclerotic Lesion Progression and Instability in Apolipoprotein E-Deficient Mice.A decrease in the percentage of circulating mDC precursors in patients with coronary heart disease: a relation to the severity and extent of coronary artery lesions?Antimonocyte chemoattractant protein-1 gene therapy reduces experimental in-stent restenosis in hypercholesterolemic rabbits and monkeys.Structure prediction and molecular dynamics simulations of a G-protein coupled receptor: human CCR2 receptor.
P2860
Q27003124-AB2AE4B9-DF6E-4AAB-9E61-E5275DFA661CQ28565946-A8C7E1A4-F08C-4E33-9036-CEF15AB0E39AQ28576184-1106DF83-9B44-4CF5-9BC9-862C3125FCDBQ29347118-B95C9919-DDB3-4C70-B05A-311AA5E7D58CQ30406302-2152987B-AE55-43C4-81A3-EB4FD543F28BQ30429015-0957037E-0E28-4210-B709-BC336BCD6BDCQ30438867-73791032-3E55-44C0-A100-0179545B4EDEQ33648166-F7DBA78E-EC85-4E2D-B12F-30D3380CCD85Q34044018-A40CAAA3-A8AF-4B15-A101-535A768025F4Q34201044-17F709D0-9ED0-4BD6-A2BF-1B689842286DQ34287120-BE54D76E-C86B-4227-AC60-ADD93FE8B27FQ34550016-615D4BB9-2CF6-43E1-A7CE-855FA04F1753Q34778960-B22F1B6A-EF78-4D23-8F6E-075B19408264Q34806027-05B51E1A-2C77-48AB-92C7-B0CA5551BEBCQ35102859-16019604-D633-4686-BE13-31706D6FE0F1Q35147977-F19C16EC-DAFB-45A0-8BE5-2046866BD5DAQ35640438-B9AF7FDF-93E8-412B-9065-19C35A7F7673Q35659436-19D6216C-1949-43C9-B6B3-9CC4DF6E78C0Q35696305-C85CF8FD-8B14-4A2F-97E8-A1CB592CC433Q36099980-30025D29-422B-4818-B4E2-2EF0AC94BBABQ36261887-E7371863-E577-4F41-B7C7-5DB9EEBFB482Q36573968-67F73734-7C3C-4477-853A-E2776EE777F5Q37304014-C0D09561-B6D1-45BD-86CA-C849FF7C21A7Q37396582-6D346E57-E644-407A-B82D-C35CB8437EBFQ37486616-E2C7C957-17CD-4C7A-B639-055C153C43B8Q37660659-139AA1BF-8FFC-4D1C-9A58-AD4E6759CB4CQ37676966-3BBDDB42-F24E-4BD1-958A-2E475E98B934Q37723178-E10A104A-7A77-4F4E-9563-23FF10A2D9C6Q37780104-28B188C2-07AE-4791-A384-38E241F1CC45Q37981725-33519F91-079C-48F0-89AF-3830AB8793E5Q38261198-974BEFEE-4D41-4F90-898B-FEEB2F7D8A7EQ38422308-806F2B6C-3F12-441B-8624-F92CFEA34036Q38578275-347F9A92-2B87-4753-BB83-611E78EE3B63Q39079401-437939A9-68A2-4879-A0E4-9A8926D6E468Q39293450-C921A537-99CD-4D82-817A-3778DAB3B3BAQ40708629-9339CB17-2AF3-40C6-9F09-E7F843C1E2D1Q41673298-5A3B5008-93D9-492A-B7AF-368F24249D24Q44985231-FDCD59DC-8732-4D80-8F83-CD1030A439F1Q45875756-35C2FF25-4262-4885-B245-A19A8189F7E8Q45901542-05D66A2A-C55E-477F-A42C-E876C7DAA16D
P2860
Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Anti-monocyte chemoattractant ...... polipoprotein E-knockout mice.
@en
Anti-monocyte chemoattractant ...... polipoprotein E-knockout mice.
@nl
type
label
Anti-monocyte chemoattractant ...... polipoprotein E-knockout mice.
@en
Anti-monocyte chemoattractant ...... polipoprotein E-knockout mice.
@nl
prefLabel
Anti-monocyte chemoattractant ...... polipoprotein E-knockout mice.
@en
Anti-monocyte chemoattractant ...... polipoprotein E-knockout mice.
@nl
P2093
P921
P1433
P1476
Anti-monocyte chemoattractant ...... polipoprotein E-knockout mice.
@en
P2093
Akira Takeshita
Ken-ichi Hiasa
Ken-ichi Nishida
Kensuke Egashira
Kisho Otani
Makoto Usui
Minako Ishibashi
Shiro Kitamoto
Shujiro Inoue
P304
P356
10.1161/01.CIR.0000038140.80105.AD
P407
P577
2002-11-01T00:00:00Z